Lewis P, Griffin S, Marsden P, Gee T, Nunan T, Malsey M, Dussek J
Clinical PET Centre, London, UK.
Lancet. 1994 Nov 5;344(8932):1265-6. doi: 10.1016/s0140-6736(94)90753-6.
Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (18FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with "operable" non-small-cell lung cancer who underwent 18FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET identified unsuspected malignant lesions in 10 (29%) patients. Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body 18FDG PET improves preoperative assessment of lung cancer patients.
尽管使用了计算机断层扫描，但仍有一些肺癌患者在手术时被发现患有无法切除的疾病，或者他们早期就出现了转移。我们研究了使用18F-氟脱氧葡萄糖（18FDG）进行全身正电子发射断层扫描（PET）是否会改善术前转移灶的检测。我们回顾性分析了34例“可手术”的非小细胞肺癌患者，这些患者在常规评估后接受了18FDG PET检查。对PET扫描和确诊检查所导致的治疗方案改变进行了评估。PET在10例（29%）患者中发现了意外的恶性病变。14例（41%）患者的治疗方案发生了改变，其中6例（18%）患者改为非手术治疗。这些数据表明，全身18FDG PET改善了肺癌患者的术前评估。
